Not yet taking people in United StatesPhase 4
Letermovir for R+ Study
Key facts
- Who runs it
- University of Wisconsin, Madison
- Where
- Madison, United StatesSee the site
- Trial code
- Status
- Not yet recruiting
- Phase
- Phase 4
- People taking part
- 146 people, planned
- Started
- Oct 2026
- Expected to end
- Sept 2029
- Type of study
- Interventional
- Treatments tested
- Letermovir
- Record updated
- 29 September 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- Adults who are at moderate risk for CMV after transplant (CMV IGG+, including D+/R+ or D-/R+)
- Adults who received a kidney transplant, liver transplant, or any combination thereof
Who cannot take part
- Known contraindication to letermovir or its excipients
- Current participation in another CMV related study
- Unwilling or unable to participate in the study protocol
Where in United States
- University of Wisconsin - MadisonMadison, United StatesContact: Office of Clinical Research Department of SurgeryNo longer taking part
About the trial
What the trial wants to find out
The purpose of this clinical trial is to find out whether a medication, called letermovir, can help prevent a virus called cytomegalovirus (CMV) in participants who receive a kidney or liver transplant and who have already been exposed the CMV.
Read full original descriptionShow less
Participants will take letermovir for 84 days.
The group in the trial
- Receive letermovirTreatment being tested
Participants will take letermovir
Treatment: Letermovir
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- An Interventional Study of Letermovir for Primary Prophylaxis of Cytomegalovirus Infection in Moderate Risk (R+) Abdominal Solid Organ Transplant Recipients
- Record updated
- 29 September 2026